Melrilimab
Based on 1 Customer Validation
Melrilimab (GSK 3772847; CNTO-7160) is a humanized IgG2σ monoclonal antibody that targets the IL-33 receptor ST2 and blocks the IL-33/ST2 signaling pathway by binding to the ST2 protein. Melrilimab is applicable to research related to asthma and atopic dermatitis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 96.07%
- No. CAS: 2222865-46-3
- Peso molecular:145.2 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human IgG2 kappa
Human
|
ST2 |
Melrilimab effectively binds to its target in vivo, inhibits serum free sST2 and accumulates total sST2, but fails to significantly improve the clinical symptoms of asthma and atopic dermatitis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 2222865-46-3
-
Appearance Liquid
-
Peso molecular 145.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Melrilimab]
-
Synonyms
GSK 3772847; CNTO-7160
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Sheng F, et al. IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential. Frontiers in immunology. 2025;16:1533335. [Content Brief]
[2]. Timotievich ED, et al. Role of Cytokines IL-25, IL-33, and TSLP in the Respiratory Tract Inflammation: Therapeutic Perspectives. Biochemistry. Biokhimiia. 2026 Jan;91(1):17-38. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz